- Home
- MGRX vs ADAP Comparison
MGRX vs ADAP Comparison
Compare MGRX & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- ADAP
- Stock Information
- Founded
- MGRX 2021
- ADAP 2008
- Country
- MGRX United States
- ADAP United Kingdom
- Employees
- MGRX N/A
- ADAP N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- ADAP Health Care
- Exchange
- MGRX Nasdaq
- ADAP Nasdaq
- Market Cap
- MGRX 23.3M
- ADAP 21.3M
- IPO Year
- MGRX 2023
- ADAP 2015
- Fundamental
- Price
- MGRX $2.27
- ADAP $0.06
- Analyst Decision
- MGRX
- ADAP Hold
- Analyst Count
- MGRX 0
- ADAP 6
- Target Price
- MGRX N/A
- ADAP $1.02
- AVG Volume (30 Days)
- MGRX 201.9K
- ADAP 62.3M
- Earning Date
- MGRX 11-13-2025
- ADAP 11-12-2025
- Dividend Yield
- MGRX N/A
- ADAP N/A
- EPS Growth
- MGRX N/A
- ADAP N/A
- EPS
- MGRX N/A
- ADAP N/A
- Revenue
- MGRX $516,030.00
- ADAP $65,084,999.00
- Revenue This Year
- MGRX N/A
- ADAP N/A
- Revenue Next Year
- MGRX N/A
- ADAP $52.35
- P/E Ratio
- MGRX N/A
- ADAP N/A
- Revenue Growth
- MGRX N/A
- ADAP N/A
- 52 Week Low
- MGRX $1.32
- ADAP $0.04
- 52 Week High
- MGRX $7.66
- ADAP $1.17
- Technical
- Relative Strength Index (RSI)
- MGRX 61.49
- ADAP 38.42
- Support Level
- MGRX $2.07
- ADAP $0.06
- Resistance Level
- MGRX $2.48
- ADAP $0.07
- Average True Range (ATR)
- MGRX 0.28
- ADAP 0.01
- MACD
- MGRX 0.01
- ADAP 0.01
- Stochastic Oscillator
- MGRX 67.51
- ADAP 53.33
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.